skip to Main Content

Refining the Molecular Framework for Pancreatic Cancer with Single-Cell and Spatial Technologies

Newsfeed image, light gray text on dark gray background
Pancreatic ductal adenocarcinoma (PDAC) is a treatment-refractory malignancy in urgent need of a molecular framework for guiding therapeutic strategies. Bulk transcriptomic efforts over the past decade have yielded two broad consensus subtypes: classical-pancreatic/epithelial versus basal-like/squamous/quasi-mesenchymal.

While this binary classification enables prognostic stratification, it does not currently inform the administration of treatments uniquely sensitive to either subtype. Furthermore, bulk mRNA studies are challenged by distinguishing contributions from the neoplastic compartment versus other cell types in the microenvironment, which is accentuated in PDAC given that neoplastic cellularity can be low. Read more . . . 

Back To Top